Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CMPX Compass Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: CMPX
Price (delayed)
$2.1
Market cap
$290.39M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.41
Enterprise value
$255.16M
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops proprietary antibody-based therapeutics to treat multiple human diseases. The company's product candidates include CTX-009, an investigational bispecific antibody, which is in
Highlights
CMPX's debt is down by 3.8% since the previous quarter
Compass Therapeutics's quick ratio has plunged by 81% YoY and by 47% from the previous quarter
The equity has contracted by 30% YoY and by 12% from the previous quarter
Key stats
What are the main financial stats of CMPX
Market
Valuations
Earnings
Shares outstanding
138.28M
Market cap
$290.39M
Enterprise value
$255.16M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.63
Price to sales (P/S)
341.52
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
300.19
Revenue
$850,000
Gross profit
$850,000
Operating income
-$61.82M
Net income
-$55.22M
EBIT
-$55.22M
EBITDA
-$53.57M
Free cash flow
-$44.24M
Per share
Balance sheet
Liquidity
EPS
-$0.41
EPS diluted
-$0.41
Free cash flow per share
-$0.32
Book value per share
$0.8
Revenue per share
$0.01
TBVPS
$0.95
Total assets
$131.45M
Total liabilities
$21.17M
Debt
$6.38M
Equity
$110.28M
Working capital
$109.25M
Debt to equity
0.06
Current ratio
8.33
Quick ratio
7.6
Net debt/EBITDA
0.66
Margins
Efficiency
Dividend
EBITDA margin
-6,302.2%
Gross margin
100%
Net margin
-6,496.8%
Operating margin
-7,273.4%
Return on assets
-38.3%
Return on equity
-42.5%
Return on invested capital
-52.8%
Return on capital employed
-47.4%
Return on sales
-6,496.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CMPX stock price
How has the Compass Therapeutics stock price performed over time
Intraday
3.96%
1 week
15.38%
1 month
23.53%
1 year
31.25%
YTD
44.83%
QTD
10.53%
Financial performance
How have Compass Therapeutics's revenue and profit performed over time
Revenue
$850,000
Gross profit
$850,000
Operating income
-$61.82M
Net income
-$55.22M
Gross margin
100%
Net margin
-6,496.8%
The net income has declined by 22% year-on-year and by 12% since the previous quarter
The operating income has decreased by 16% YoY and by 9% from the previous quarter
CMPX's net margin is down by 12% since the previous quarter
The operating margin has declined by 9% since the previous quarter
Price vs fundamentals
How does CMPX's price correlate with its fundamentals
Growth
What is Compass Therapeutics's growth rate over time
Valuation
What is Compass Therapeutics stock price valuation
P/E
N/A
P/B
2.63
P/S
341.52
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
300.19
The EPS has declined by 17% year-on-year and by 14% since the previous quarter
CMPX's price to book (P/B) is 55% higher than its last 4 quarters average of 1.7
The equity has contracted by 30% YoY and by 12% from the previous quarter
CMPX's P/S is 36% above its last 4 quarters average of 250.8
Efficiency
How efficient is Compass Therapeutics business performance
The ROIC has plunged by 59% YoY and by 26% from the previous quarter
The return on equity has declined by 48% year-on-year and by 22% since the previous quarter
Compass Therapeutics's return on assets has decreased by 41% YoY and by 17% QoQ
The return on sales has declined by 12% since the previous quarter
Dividends
What is CMPX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CMPX.
Financial health
How did Compass Therapeutics financials performed over time
Compass Therapeutics's quick ratio has plunged by 81% YoY and by 47% from the previous quarter
CMPX's current ratio has plunged by 80% YoY and by 44% from the previous quarter
CMPX's debt is 94% smaller than its equity
The equity has contracted by 30% YoY and by 12% from the previous quarter
CMPX's debt to equity is up by 20% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.